STOCK TITAN

Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
partnership clinical trial
Rhea-AI Summary

Syneos Health (Nasdaq:SYNH) has announced a strategic partnership with Equicare to implement proXimity™, a cloud-based software platform that streamlines the transfer of clinical trial data from electronic health records (EHR) to electronic data capture systems (EDC). This innovation aims to enhance data accuracy and reduce transfer times significantly, with a proof of concept demonstrating a five-fold increase in speed and zero errors in data entry. The platform will facilitate quicker access to vital data for clinical trials, thereby accelerating the development of new therapies, particularly in oncology.

Positive
  • Partnership with Equicare enhances data transfer efficiency in clinical trials.
  • proXimity demonstrated five times faster data transfer with 0% entry errors.
  • Supports quicker access to clinical trial data for enhancing therapy development.
Negative
  • None.

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records (EHR) to the sponsor’s electronic data capture systems (EDC).

Through the partnership, Syneos Health will use the proXimity platform to automate sponsor data transfers from EHRs to EDCs for clinical trials, helping to accelerate the performance of new therapies for patients. This collaboration support’s the Company’s commitment to listening and learning from sites and adapting to meet their most critical needs.

“At Syneos Health, we are committed to our customers, always. By partnering with Equicare to use proXimity, we are further addressing challenges sites and sponsors face regarding data capture, timelines and quality control,” said Michael Henning, President, Clinical Delivery, Syneos Health. “We’re confident this collaboration will help enhance the clinical trial experience for sites and sponsors by accelerating data entry and management to improve its accuracy and to help speed new therapies to patients.”

Typically, clinical trial subject data is transcribed manually by site coordinators or other staff from the EHR to the EDC, which is time-intensive and error-prone. proXimity automates this process and transfers the selected data from one system to another without the need for manual transcription, dramatically reducing the time needed to transfer data while helping to eliminate transcription errors.

While therapeutically agnostic, the proXimity software was first selected by NEXT Oncology – part of the Syneos Health Catalyst Site Program for phase I studies – as the exclusive tool to automate the transfer of clinical trial data from their EHR to EDC systems to speed the performance of new therapies in clinical trials. The platform now serves as a key tool for clinical trial data management, as well as assists sponsors in gaining access to their data to accelerate cancer research.

In a recently conducted proof of concept exercise where NEXT Oncology utilized proXimity to transfer data from the EHR to the Syneos Health managed EDC database, the data transfer was five times faster than manual entry and the data was transferred with 0% data entry errors, compared to a 3.5% error rate for manual data entry.

“We are using proXimity today for many of our studies and we are realizing the benefits as we are delivering the data to our sponsors more quickly with less errors,” said Dr. Anthony Tolcher, MD, Medical Oncologist and co-founder of NEXT Oncology. “In 2023, NEXT Oncology will utilize proXimity on all studies that utilize Medidata Rave as the EDC. We know this is the future to bring new therapies to cancer patients faster, and we are glad to have Syneos Health’s support with this strategy.”

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.  

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.  Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. 

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.  

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.  

Syneos Health Investor Relations Contact: Syneos Health Press/Media Contact:
Ronnie SpeightGary Gatyas
Senior Vice President, Investor RelationsExecutive Director, External Communications
+1 919 745 2745+1 908 763 3428
Investor.Relations@syneoshealth.comgary.gatyas@syneoshealth.com

About Equicare Health
Equicare Health is the industry's leading provider of comprehensive care coordination solutions for oncology. EQUICARE CS™ (ECS) is a multi-facility web-based software tool that facilitates patient engagement including patient reported outcomes, patient navigation, survivorship care and a several other clinical tools. proXimity is a tool set designed to automate data transfer between EMRs and EDCs in support of sponsored clinical trials. For more information, visit please visit www.dataproXimity.com.

Equicare Health Media Contact:
Marnie Sanders
VP, proXimity
Equicare Health Inc.
+1.303.506.9050
marnie.sanders@equicarehealth.com


FAQ

What is the purpose of Syneos Health's partnership with Equicare?

The partnership aims to implement proXimity™, which streamlines data transfer from EHR to EDC, enhancing efficiency in clinical trials.

How does proXimity improve clinical trial data handling for Syneos Health?

proXimity automates data transfers, reducing manual entry errors and significantly increasing the speed of data handling.

What were the results of the proof of concept for proXimity at NEXT Oncology?

The proof of concept showed a five-fold increase in data transfer speed with zero recorded data entry errors.

How will proXimity affect future clinical trials at NEXT Oncology?

NEXT Oncology plans to utilize proXimity for all studies using Medidata Rave as the EDC in 2023, aiming to accelerate delivery of therapies to patients.

What is Syneos Health's stock symbol?

Syneos Health's stock symbol is SYNH.

Syneos Health, Inc.

NASDAQ:SYNH

SYNH Rankings

SYNH Latest News

SYNH Stock Data

4.46B
103.15M
0.49%
94.75%
6.52%
Diagnostics & Research
Healthcare
Link
United States
Morrisville